Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 […]
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Y-mAbs Announces Publication of Preclinical GD2-SADA Data globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Y-Mabs Announces Publication Of Preclinical GD2-SADA Data At 2024 ASCO Annual Meeting menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.